Selegiline: A reappraisal of its role in parkinson disease

Clinical Neuropharmacology

Volumn 35, Issue 3, 2012, Pages 134-140

  Fabbrini, Giovanni ^a   Abbruzzese, Giovanni ^b   Marconi, Stefano ^c   Zappia, Mario ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

MAO B inhibitors; Parkinson disease; selegiline

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; RASAGILINE; SELEGILINE; TOCOPHEROL;

ANXIETY DISORDER; CLINICAL EFFECTIVENESS; CONFUSION; DISEASE COURSE; DIZZINESS; DOPAMINE METABOLISM; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DYSKINESIA; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; MONOTHERAPY; MOOD; MORTALITY; NAUSEA; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VERTIGO; XEROSTOMIA;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DOPAMINE; HUMANS; PARKINSON DISEASE; SELEGILINE;

EID: 84861510378     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318255838b     Document Type: Review

References (55)

1. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937Y1943.
2. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009;24(4):564Y573.
3. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947Y954.
4. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268Y1278.
5. Sampaio C, Ferreira JJ. Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression. Nat Rev Neurol 2010;6(3):126Y128.
6. Chrisp P, Mammen GJ, Sorkin EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991;1(3):228Y248.
7. Wiseman LR, McTavish D. Selegiline: a review of its clinical efficacy in Parkinson's disease and its clinical potential in Alzheimer's disease. CNS Drugs 1995;4(3):230Y246.
8. Eldepryl. Summary of product characteristics [online]. Available at: http://www.medicines.org.uk/emc/medicine/13200. Accessed February 15, 2011.
9. Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf 1998;19(1):11Y22.
10. Yasar S, Bergman J. Amphetamine-like effect of L-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 1994; 56(6 Pt 2):768Y773.
11. Yasar S, Gaal J, Panlilio LV, et al. A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology (Berl) 2006;183(4):413Y421.
12. Barrett JS, Rohatagi S, DeWitt KE, et al. The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug Eldepryl(\) (selegiline hydrochloride). Am J Ther 1996;3(4):298Y313.
13. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage forms. J Pharm Pharmacol 1998;50(4):375Y382.
14. Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110(11):1241Y1255.
15. Youdim MB, Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 2004;25 (1Y2):243Y250.
16. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72(21 suppl 4):S1YS136.
17. Cohen G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1984;106(1):209Y210.
18. Heikkila RE, Manzino L, Cabbat FS, et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311(5985):467Y469.
19. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30(4):666Y672.
20. Ebadi M, Brown-Borg H, Ren J, et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 2006;7(11):1513Y1529.
21. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328(3):176Y183.
22. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245(4917): 519Y522.
23. Myllyla VV, Sotaniemi KA, Tuominen J, et al. Selegiline as primary treatment in early phase Parkinson's diseaseYan interim report. Acta Neurol Scand Suppl 1989;126:177Y182.
24. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38(5):771Y777.
25. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321(20):1364Y1371.
26. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001;56(12):1712Y1721.
27. Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol 1999;6(5):539Y547.
28. Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66(8): 1200Y1206.
29. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329(7466):593.
30. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58(1):11Y17.
31. National Collaborating Centre for Chronic Conditions 2006. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. Available at: http://guidance.nice.org.uk/CG35/Guidance/pdf/ English. Accessed June 7, 2011.
32. Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999;6(2):141Y150.
33. Mizuno Y, Kondo T, Kuno S, et al. Early addition of selegiline to L-dopa treatment is beneficial for patients with Parkinson disease. Clin Neuropharmacol 2010;33(1):1Y4.
34. Vans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82(10):1112Y1118.
35. Zhao YJ, Wee HL, Au WL, et al. Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism Relat Disord 2011;17(3):194Y197.
36. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder SocietyYEuropean Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006;13(11):1170Y1185.
37. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13(11):1186Y1202.
38. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561Y566.
39. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51(5):604Y612.
40. Giladi N. Medical treatment of freezing of gait. Mov Disord 2008; 23(suppl 2):S482YS488.
41. Myllyla VV, Sotaniemi K, Maki-Ikola O, et al. Role of selegiline in combination therapy of Parkinson's disease. Neurology 1996; 47(6 suppl 3):S200YS209.
42. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in adVanced Parkinson's disease. Clin Neuropharmacol 1988;11(1):45Y55.
43. Lieberman AN, Gopinathan G, Neophytides A, et al. Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med 1987;87(12):646Y649.
44. Sivertsen B, Dupont E, Mikkelsen B, et al. Selegiline and levodopa in early or moderately adVanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurol Scand Suppl 1989;126:147Y152.
45. Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and ''wearing off '' symptoms. Clin Neuropharmacol 2007;30(5):295Y300.
46. Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19(4): 426Y432.
47. Ondo WG, Hunter C, Isaacson SH, et al. Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17(2):117Y118.
48. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241Y248.
49. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995;311(7020):1602Y1607.
50. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998;316(7139):1191Y1196.
51. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43(3):318Y325.
52. Olanow CW, Myllyla VV, Sotaniemi KA, et al. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998;51(3):825Y830.
53. Macleod AD, Counsell CE, Ives N, et al. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev 2005;(3):CD004898.
54. Nandagopal JJ, DelBello MP. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin Pharmacother 2009;10(10):1665Y1773.
55. Kahn R, Gorgon L, Jones K, et al. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res 2012;14(3):377Y382.